Regeneron to buy bankrupt DNA testing firm 23andMe for $256 million
Drugmaker Regeneron Pharmaceuticals will buy genetic testing firm 23andMe Holding for $256 million through a bankruptcy auction, the companies said on Monday.
You are not logged in so some information on this page has been withheld. To see more, please log in.